<DOC>
	<DOCNO>NCT01270373</DOCNO>
	<brief_summary>The purpose study evaluate usual reverse sequence anthracycline follow taxane locally advanced breast cancer .</brief_summary>
	<brief_title>NeoSAMBA : Neoadjuvant : Does Sequence Anthracycline Taxane Matters : Before After ?</brief_title>
	<detailed_description>Anthracylines taxanes active chemotherapy agent treatment breast cancer . The usual sequence anthracycline follow taxane due timing discovery introduction treatment armamentarium . More recent evidence suggest pre clinical well clinical rational reverse sequence . The neoadjuvant approach allow quick evaluation different treatment strategy . At time , study collect tissue biopsy blood different time point order evaluate predictive biomarkers .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>1 . Stage IIB IIIB HER2 negative breast cancer 2 . ECOG performance status ≤ 2 3 . Neuropathy grade &lt; 1 Common Terminology Criteria Adverse Events version 3.0 ( CTCAE v 3.0 ) 4 . Adequate hematologic function : Absolute neutrophil count ( ANC ) &gt; 1500/μL Platelets ≥100,000/μL Hemoglobin ≥ 9 g/dL 5 . Adequate hepatic renal function : Serum bilirubin ≤ 1.5 x institutional upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤2.5 x institutional ULN Alkaline phosphatase ≤2.5 x institutional ULN Serum creatinine ≤1.5 x ULN calculate creatinine clearance ≥ 50 mL/min 6 . Adequate cardiac function Left ventricular ejection fraction ( LVEF ) within institutional normal range 7 . Knowledge investigational nature study ability provide consent study participation Exclusion criteria 1 . Pregnancy 2 . Bilateral , synchronous breast cancer 3 . Previous diagnosis breast cancer 4 . Any disease ( ) , psychiatric condition , metabolic dysfunction , contraindicate use study drug would make patient inappropriate study</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>neoadjuvant therapy</keyword>
	<keyword>drug therapy</keyword>
</DOC>